Cardiol Therapeutics Inc. Appoints Dr. Timothy Garnett to Strengthen Board Leadership
- Cardiol Therapeutics Inc. appoints Dr. Timothy Garnett as a director to strengthen its leadership team.
- Dr. Garnett brings over 30 years of pharmaceutical experience, enhancing Cardiol's capabilities in metabolic therapies.
- The appointment reflects Cardiol's commitment to innovation and board diversity, succeeding Michael Willner's contributions since 2021.
Cardiol Therapeutics Strengthens Leadership with New Board Appointment
In a strategic move to bolster its leadership, Cardiol Therapeutics Inc. announces the appointment of Dr. Timothy Garnett as a director following its Annual General Meeting of Shareholders on May 28, 2025. Dr. Garnett brings a wealth of experience to the company, having spent over 30 years in the pharmaceutical sector, with a significant portion of that time at Eli Lilly and Company. His tenure there includes serving as Chief Medical Officer from 2008 until his retirement in 2021, where he played a pivotal role in the development and commercialization of therapeutics in areas such as women’s health, endocrinology, and neuroscience. This extensive background positions him as a valuable asset to Cardiol Therapeutics as the company continues to navigate the complex landscape of metabolic therapies.
Dr. Garnett’s expertise encompasses multiple facets of pharmaceutical development, including clinical development, regulatory strategy, and safety management. His proven track record of overseeing global commercial launches and managing diverse product portfolios aligns well with Cardiol's objectives to innovate and expand within the therapeutic space. Additionally, Dr. Garnett’s current roles as Chair of Ophirex and Director at MapLight Therapeutics, along with his advisory position at Cambridge Innovation Capital, illustrate his active involvement in shaping the future of pharmaceutical advancements. As Cardiol Therapeutics seeks to enhance its strategic direction and operational capabilities, Dr. Garnett’s insights from both his extensive industry experience and leadership roles are expected to contribute significantly.
The appointment also signifies a transition for Cardiol Therapeutics as it thanks Michael Willner for his contributions as a Board member since September 2021. Willner's ongoing support in an advisory capacity highlights the company’s commitment to maintaining a strong governance structure while integrating new leadership. This change reflects Cardiol's ambition to enhance its board diversity and strategic oversight, ensuring that it remains at the forefront of innovation in the therapeutics market.
In other developments, Cardiol Therapeutics aims to accelerate its research and development initiatives, fostering a culture of innovation and scientific excellence. The company’s focus on metabolic therapies positions it uniquely as the demand for advanced treatments continues to rise, particularly in chronic conditions that impact quality of life. With Dr. Garnett’s appointment, Cardiol Therapeutics is poised to enhance its strategic objectives and operational execution.